Biochemist studies when enzymes in our cells go wrong and misbehave in human disease.
University of Delaware researcher awarded NIH grant to study why eraser enzymes go wrong and lead to cancer.
University of Delaware biochemist Jeff Mugridge is trying to figure out how so-called mRNA eraser enzymes work in our cells, why those erasers can sometimes misbehave and lead to cancer, and how science can pave the way for possible solutions to this problem.
Ribonucleic acid (RNA) is a single-stranded molecule that is copied from the DNA in our bodies. Messenger RNA (mRNA) molecules carry the instruction code that tells our cells how to do everything they need to survive, such as when, where and how to make proteins or enzymes.
One of the many ways the cells in our bodies control mRNA molecules is to decorate them with different chemical groups that either subtly or drastically change the way that messages are conveyed.
Mugridge, assistant professor of chemistry and biochemistry, was recently awarded $1,956,466 from the National Institutes of Health (NIH) to study specific enzymes that can act like erasers and remove critical chemical groups, called methyl groups, found on mRNA molecules.
With hard-to-treat cancers like glioblastoma, sometimes these methyl eraser enzymes are overexpressed in cancer cells meaning too many eraser enzymes are working at once. This can cause mRNA molecules to lack important information, which can change the messages they deliver in a way that leads to cancer progression and tumor growth.
University of Delaware Assistant Professor Jeff Mugridge is studying eraser enzymes that can remove important chemical groups from mRNA, the molecules in our bodies that carry instructions and code to tell our cells how to function. The work has the potential to inform treatment options for various human diseases where these eraser enzymes misbehave. Credit: Photo by Evan Krape
Little is known about how these eraser enzymes decide which methyl groups to eliminate or keep, how often they erase methyl groups in healthy cells or why they misbehave in some human diseases.
Along with two doctoral students working in his lab, Mugridge is specifically looking at a class of eraser enzymes called RNA demethylases. Demethylases remove methyl groups on RNA that play important roles in gene expression and the progression of cancers like glioblastoma or acute myeloid leukemia.
RNA methylation is a biochemical process that can act like a switch and turn certain activities on or off in our cells. It is known to be important for producing properly shaped RNA molecules, synthesizing proteins and determining the lifespan of RNA molecules in the cell, among other things. Methyl modifications on mRNA also play a role in cell fate decisions and the way embryonic stem cells are differentiated during development.
Scientists have recently identified a few RNA methyl modification erasers, which has raised the intriguing possibility that these methyl groups can be both written and erased from an mRNA transcript, Mugridge said. But how these eraser enzymes recognize and choose which specific methyl groups to remove out of the thousands that are found on RNA, and how frequently they do this, remains poorly understood.
Does it happen all the time, or is it a rare event? Does it only happen in disease or in specific cell types? These are some of the questions Mugridge and his team plan to answer. The research team also will explore how proteins and other cofactors, such as vitamin C, regulate demethylase activity in the cell.
Long-term, if we have a high-resolution picture of how these demethylase enzymes work, then we can begin to understand how each eraser is linked to different human diseases and disease progression, said Mugridge. This will give us better information about which of these enzymes to target for inhibition and how, for example, to slow down tumor progression in cancer.
For instance, in glioblastoma an eraser enzyme known as FTO is overexpressed, meaning the glioblastoma cells make much more of it compared to normal cells. This leads to a lot of methyl-erasing activity on RNA in those cancer cells, which seems to be important for cancer progression. Research has shown that when FTO is inhibited with a drug, it slows down cancer progression in glioblastoma. However, therapeutics that can selectively and effectively target RNA demethylase enzymes to treat cancers have eluded scientists.
If Mugridge and his team can figure out the molecular details of how these demethylase enzymes work and how the cell controls their functions, they could look for ways to manipulate which methyl groups get erased from RNA and pave the way for therapeutics that help correct misbehaving eraser enzymes in disease.
If we understood how the RNA molecule binds, exactly where it binds on the protein surface and how it interacts with specific amino acids that make up the protein, we might be able to fill in the missing pieces of the puzzle and then develop tools to monitor or influence this erasing activity in cells, he said.
In Brown Laboratory, Mugridge and his students produce proteins in bacterial cells and then purify and isolate the specific RNA demethylases of interest. Brittany Shimanski, a doctoral student from the Chemistry-Biology Interface program, is using these purified enzymes to conduct biochemistry and structural biology studies to better understand how the eraser enzymes function and select their targets.
Mugridge explained that if the team can grow crystals of the proteins in complex with the modified RNA groups that they act on, they can take them to a national lab and shoot them with high-intensity X-rays to get 3D images of the enzymes shape, including information about where all the atoms are located and how the enzymes bind to the methylated RNA that they are going to erase.
This atomic-scale structural biology information can provide critical insights into how an enzyme works and will also inform doctoral student Luke Calzinis work to understand how these eraser enzymes are controlled by different proteins or small-molecule co-factors, such as vitamin C, that can change their activity or selectivity.
The work could give scientists new ways to ask specific questions in cells, too.
We feel like were working on an important problem that could be significant for understanding how different diseases work and how they are impacted by changes in RNA methylation, said Mugridge.
The new five-year project is funded through NIHs Maximizing Investigators Research Award (MIRA) program.
Continue reading here:
Why Eraser Enzymes Go Wrong and Lead to Cancer - SciTechDaily
- Japan Stem Cells Market to be at Forefront by 2028 - November 24th, 2022
- Mice Model Technologies Market Outlook, Competitive Landscape and Forecasts to 2031 - openPR - October 13th, 2022
- Cell & Tissue Preservation Market Size will Observe Lucrative Surge by the End 2031 - openPR - October 13th, 2022
- PRP and PRF in Cosmetics Market Growth Opportunities Analysis Report - openPR - October 13th, 2022
- Orthobiologics Market to Receive Overwhelming Hike in Revenues by 2031 - openPR - October 13th, 2022
- Stem Cells Market is Expected to Grow with High Probability Business Opportunity by 2028 - Digital Journal - October 4th, 2022
- External Beam Radiation Therapy Market: Growing Awareness about Early Detection and Diagnosis of various Cancer Types to Drive the Market - BioSpace - September 16th, 2022
- DiMethyl Sulfoxide (DMSO) Market to Touch US$ 838.6 Million in 2032 Owing to its Widespread Application in End-Use Industries & Anti-Inflammatory... - September 16th, 2022
- Virology Market Growth Prospects, Trends and Forecast up to 2030 - BioSpace - September 8th, 2022
- Cell Banking Outsourcing Market is Driven by Rising Number of Stem Cell Therapies across the Globe - BioSpace - September 8th, 2022
- Regenerative Therapies Market 2018 By Emerging Trends, Industry Share, Regional Overview and SWOT Analysis till 2026 - Digital Journal - August 22nd, 2022
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market Trends, Competitive Landscape and Regional Insights to 2031 - BioSpace - August 14th, 2022
- Multiphoton Microscopy Market Insights, New Innovations, Research and Growth Factor till 2031 - BioSpace - August 14th, 2022
- Buffalo center fuels research that can save your life from heart disease and stroke - Buffalo News - August 5th, 2022
- Drug Discovery Services Market is Expected to Witness Significant Growth between 20212031 - BioSpace - July 27th, 2022
- Stem Cells Market to Expand at a CAGR of 10.4% from 2021 to 2028 Travel Adventure Cinema - Travel Adventure Cinema - July 27th, 2022
- Dental Membrane and Bone Graft Substitutes Market to Exceed Value of US$ 1,337 Mn by 2031 - PR Newswire UK - July 27th, 2022
- Lipid Disorder Treatment Market is Projected to Experience Promising Growth Opportunities in the Forthcoming Years - BioSpace - July 27th, 2022
- Immunoglobin Products Market to Witness Comprehensive Growth by 2031 - BioSpace - July 19th, 2022
- Antibody Therapy Market Propels at a Robust CAGR of 13.2% due to Rising Cancer and Other Chronic Disease Prevalence Future Market Insights, Inc. -... - July 19th, 2022
- Orthobiologics Market is Predicted to Expand at a CAGR of 4.7% during the Forecast Period, notes TMR Study - GlobeNewswire - July 11th, 2022
- Cell Line Development Market: Increase in Prevalence of Cancer and Other Chronic Diseases to Drive the Market - BioSpace - July 11th, 2022
- Transplant Diagnostic Market: Increase in Number of Cancer & Blood Disorder Patients to Drive the Market - BioSpace - July 11th, 2022
- Microscopy Devices Market Competitive Insights and Precise Outlook 2021-2028 Industrial IT - Industrial IT - June 4th, 2022
- Neoantigen Targeted Therapies Market Analysis and Opportunity Assessment up to 2027 - BioSpace - June 4th, 2022
- MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of... - August 31st, 2021
- Incyte and MorphoSys Announce the European Commission Approval of Minjuvi (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults... - August 31st, 2021
- Rock snot discovered in another Pennsylvania waterway - pennlive.com - September 12th, 2020
- Bone Marrow and Stem Cell Transplants ChristianaCare - June 20th, 2020
- 'Billion Dollar Burger' Asks: What Is Meat? - Delaware First Media - June 17th, 2020
- Data from Incytes Oncology Portfolio Accepted for Presentation at the ASCO and EHA Virtual Meetings - Yahoo Finance - May 20th, 2020
- Stem Cell therapy Middletown Delaware 19709 - February 10th, 2020
- First CAR-T cell cancer therapy patient in Delaware - Dover Post - February 10th, 2020
- Gore, Mayo Clinic team up to deliver breakthrough medical therapies - Plastics Today - December 17th, 2019
- Global Stem Cell Therapy Market 2019-2025 Analyzed by Business Growth, Development Factors, Applications, and Future Prospects - Technology Magazine - December 17th, 2019
- From inspiration to innovation | UDaily - UDaily - November 14th, 2019
- What Will Happen to Actinium Pharmaceuticals Inc (delaware (NYSEAMERICAN:ATNM) Next? The Stock Has Increase in Shorts - The Lamp News - October 26th, 2019
- Could Fate Therapeutics, Inc. (FATE) Recover After Forming a Bearish Head & Shoulders Pattern? - The Altcoin Mercury - September 25th, 2019
- Stem Cell therapy Lewes Delaware 19958 - September 14th, 2019
- Westfield High School Principal Derrick Nelson was 'gift ... - May 16th, 2019
- SignalRx - March 22nd, 2019
- Stem Cell therapy Newark Delaware 19725 - February 27th, 2019
- Stem Cell therapy Wilmington Delaware 19810 - February 27th, 2019
- Stem Cell Therapy | Regenerative Delaware - February 22nd, 2019
- Regenerative Cell Treatment &Therapy - Delaware ... - February 22nd, 2019
- Stem Cell Doctors Delaware, Stem cell injections, Stem ... - October 14th, 2018
- Regenerative Cell Therapy - Delaware Integrative Medicine - June 22nd, 2018
- FDA Cracks Down On Stem-Cell Clinics Selling Unapproved Treatments - Delaware First Media - August 30th, 2017
- Detroit Lions' Paul Worrilow has beaten odds, inspires others to help - Detroit Free Press - July 2nd, 2017
- Lions LB Paul Worrilow Making A Difference On And Off The Field - FanRag Sports (blog) - July 2nd, 2017
- Lions LB Paul Worrilow gave stem cells to anonymous leukemia patient - Detroit Free Press - March 11th, 2017
- Delaware (Stem Cell) - what-when-how - November 3rd, 2016
- University of Delaware Chemical Engineering - October 31st, 2015
- Home | www.papoutsakis.org - October 4th, 2015
- Stem Cells - Eppendorf - October 2nd, 2015
- Efficient Differentiation of Mouse Embryonic Stem Cells ... - October 1st, 2015
- Alpine Rose Leaf Extract for Environmental Protection for ... - October 1st, 2015
- De-Differentiation of Somatic Cells to a Pluripotent State ... - June 29th, 2015
- DSU AgDiscovery 2015 - Investing in the Future of American ... - June 1st, 2015
- Stem-cell battles: Stem-cell research in the USA is facing ... - April 9th, 2015
- IPS Stem Cells: New Ethical Quandaries - Santa Clara ... - December 27th, 2014
- The California Cloning and Stem Cell Laws - December 27th, 2014
- Can a bodys own stem cells help heal a heart? - October 19th, 2014
- Delaware Stem Cell Treatment | Stem Cell Treatments - September 9th, 2014
- Core mechanism for root growth identified - August 25th, 2014
- Stem Cell Companies - A Comprehensive Overview - August 23rd, 2014
- Stem Cell Doctors, Physician Team, Our Doctors - August 23rd, 2014
- California Stem Cell Report: California Stem Cell Agency ... - August 23rd, 2014
- Bone Marrow and Stem Cell Transplants - Christiana Care ... - August 22nd, 2014